BC Innovations | Apr 9, 2009
Targets & Mechanisms

Susceptibility loci for COPD

A genomewide association study from GlaxoSmithKline plc and Duke University has identified two new susceptibility loci for COPD that might not only help assess disease risk, but also lead to new therapeutic targets. 1 A...
BC Week In Review | Feb 2, 2009
Clinical News

Formoterol Modulite regulatory update

EMEA's CHMP recommended against use of Chiesi's formoterol 12 µg to treat asthma in children ages 5-12 years because efficacy could not be demonstrated in the age group. The formoterol hydrofluoroalkane (HFA)-based propelled metered dose...
BC Week In Review | Jun 23, 2003
Clinical News

Formoterol Modulite: IND

Chiesi's U.S. division, Chiesi Pharmaceuticals Inc., submitted an IND to the FDA. Chiesi Farmaceutici S.p.A. , Parma, Italy   Product: Formoterol Modulite   Business: Pulmonary   Molecular target: NA   Description: Formoterol hydrofluoroalkane (HFA)-based propelled metered...
Items per page:
1 - 3 of 3